Table 2.
Summary of patient, liver function, tumour and treatment characteristics
| Range (%) | |
| Age | 59 (31-66) |
| Gender (male), n (%) | 6 (100) |
| Type of graft | |
| Whole | 4 (67) |
| Right lobe | 2 (33) |
| Within UCSF, n (%) | 4 (67) |
| Time to first recurrence (mo) | 18.5 (1.2-69.4) |
| Time to index recurrence (mo) | 66.5 (1.2-86.7) |
| ECOG | 1 (0-1) |
| Bilirubin (umol/L) | 9 (4-23) |
| Albumin (g/L) | 43 (39-47) |
| ALT (U/L) | 28 (19-44) |
| AST (U/L) | 33 (18-58) |
| INR | 1.0 (1.0-1.5)1 |
| Platelet (× 109/L) | 124 (43-255) |
| Creatinine (umol/L) | 107 (78-121) |
| Index lesion as first recurrence, n (%) | 4 (44) |
| Number of index lesions | 1 (1-2) |
| Tumour size (cm) | 2.3 (0.7-3.6) |
| IVC invasion, n (%) | 2 (22) |
| Distant recurrence, n (%) | 1 (11) |
| AFP (ng/mL) | 4 (2-1354) |
| Prescribed dose (Gy) | 45 (37.5-50) |
| Number of fractions | 5 (5-6) |
| Dose per fraction (Gy) | 8 (7.5-10) |
| Treatment duration (d) | 5 (5-14) |
| Concomitant sysetmic treatment, n (%) | 6 (100) |
1
One patient on warfarin had INR ≥ 1.5. ECOG: Eastern Cooperative Oncology Group; INR: International normalized ratio; ALT: Alanine transaminase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; USCF: University of California San Francisco; IVC: Inferior vena cava.